Loading…
The patent supports nerve sensing, mapping, and targeted therapy.
Autonomix Medical, Inc. (Nasdaq: AMIX) announced the expansion of its Precision Neuromodulation Platform with a new U.S. patent. This patent provides broad coverage for nerve sensing, mapping, and targeted therapy technologies.
The new patent enhances Autonomix's intellectual property portfolio, reinforcing its position in the medical device industry. The company continues to innovate in the field of neuromodulation, aiming to improve patient outcomes through advanced technology.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.